Should we be CHARMed?
- PMID: 17567867
- DOI: 10.1002/ibd.20191
Should we be CHARMed?
Comment on
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.Gastroenterology. 2007 Jan;132(1):52-65. doi: 10.1053/j.gastro.2006.11.041. Epub 2006 Nov 29. Gastroenterology. 2007. PMID: 17241859 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources